Clinical Trial

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Name: SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors — clinical trial record (NCT05245058)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

To evaluate the safety and tolerability of SPH5030 tablets in subjects with HER2-positive advanced solid tumors

Protocol Amendment History 12 amendments

This ClinicalTrials.gov record has been amended 12 times since 2022-02-09; most recent amendment 2026-04-29.

Trial Details

NCT Number	NCT05245058
Lead Sponsor	Shanghai Pharmaceuticals Holding Co., Ltd
Conditions	HER2-positive Advanced Solid Tumors
Enrollment	150 participants
Start Date	2022-01-21
Primary Completion	2026-12-21 (estimated)
Study Completion	2026-12-21 (estimated)
Updated on ClinicalTrials.gov	2026-05-05